Robertson, Neil

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

Tuohy, O., Costelloe, L., Hill-Cawthorne, G., Bjornson, I., Harding, K., Robertson, N., May, K., Button, T., Azzopardi, L., Kousin-Ezewu, O., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 238

Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution

Matthews, L., Marasco, R., Jenkinson, M., Küker, W., Luppe, S., Leite, M. I., Giorgio, A., De Stefano, N., Robertson, N., Johansen-Berg, H., et al. (2013) · Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 225

Leber's hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis

Kellar‐Wood, H., Robertson, N., Govan, G. G., Compston, D. A. S., & Harding, A. E. (1994) · Annals of Neurology

Multiple Sclerosis Research StudiesMitochondrial Function and Pathology

Cited by 145

Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features

Pariani, N., Willis, M., Muller, I., Healy, S., Nasser, T., McGowan, A., Lyons, G., Jones, J., Chatterjee, K., Dayan, C., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsOphthalmology and Eye Disorders

Cited by 84

Multiple sclerosis relapses and depression

Moore, P., Hirst, C., Harding, K. E., Clarkson, H., Pickersgill, T. P., & Robertson, N. P. (2012) · Journal of Psychosomatic Research

Multiple Sclerosis Research StudiesCancer survivorship and care

Cited by 80

2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy

Muller, I., Moran, C., Lecumberri, B., Decallonne, B., Robertson, N., Jones, J., & Dayan, C. M. (2019) · European Thyroid Journal

Thyroid Disorders and TreatmentsOphthalmology and Eye Disorders

Cited by 78

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme

Palace, J., Duddy, M., Lawton, M., Bregenzer, T., Zhu, F., Boggild, M., Piske, B., Robertson, N. P., Oger, J., Tremlett, H., et al. (2019) · Journal of Neurology, Neurosurgery & Psychiatry

Multiple Sclerosis Research StudiesHealth Systems, Economic Evaluations, Quality of Life

Cited by 44

Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years

Muller, I., Willis, M., Healy, S., Nasser, T., Loveless, S., Butterworth, S., Zhang, L., Draman, M. S., Taylor, P. N., Robertson, N., et al. (2018) · Thyroid

Thyroid Disorders and TreatmentsMultiple Sclerosis Research Studies

Cited by 34

The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic

Tallantyre, E. C., Causon, E. G., Harding, K. E., Pickersgill, T. P., & Robertson, N. P. (2015) · Multiple Sclerosis Journal

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 18